Cadila gets USFDA nod for its drug

Mumbai, July 20 (UNI) Cadila Healthcare Ltd has received approval from the USFDA to market Meloxicam Tablets, which are used for treating pain and inflammation, in the US market.

Informing the BSE, the company said it received the approval to market the nonsteroidal anti-inflammatory drug in the strengths of 7.5 mg and 15 mg. Branded sales of Meloxicam Tablets in the US market in 2005, were pegged at Dollar 1.26 billion.

This marks the sixteenth ANDA (Abbreviated New Drug Application) approval for the group since the commencement of filing process in FY 2003-04 and the group has filed 37 ANDAs and 40 DMFs (drug master files) so far, the company said.

Meloxicam falls in the pain management segment and is used to relieve the symptoms of arthritis, primary dysmenorrhoea and as an analgesic.

UNI SN GB AG1428